News NICE will only fund Opdivo in PD-L1 lung cancer patients Pharma must apply for Cancer Drugs Funding in restricted population - NICE
News NICE rejects Keytruda in lung cancer, points to price and da... Cancer immunotherapy too expensive.
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
